A 12-year population-based study of psychosis in Parkinson disease.
about
The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's diseaseThe treatment of hallucinations in schizophrenia spectrum disordersLipid pathway alterations in Parkinson's disease primary visual cortexUpdate on the treatment of Parkinson’s disease psychosis: role of pimavanserinA systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.Cortical and Striatal Reward Processing in Parkinson's Disease Psychosis.Pimavanserin (Nuplazid): A Treatment for Hallucinations and Delusions Associated With Parkinson's Disease.Correlation of sleep disturbance and cognitive impairment in patients with Parkinson's disease.Parkinson's disease: the quintessential neuropsychiatric disorderPatterns and trends in antipsychotic prescribing for Parkinson disease psychosisAlzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's diseaseHallucinations and sleep disorders in PD: ten-year prospective longitudinal studyTreatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.Behavioral effects of levodopa.Psychiatric aspects of Parkinson's disease.Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptomsNew wine in old bottle: late-life psychosisTrigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort studyCerebral correlates of psychotic syndromes in neurodegenerative diseasesDiagnostic tools for REM sleep behavior disorder.Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects.Affective Disorders, Psychosis and Dementia in a Community Sample of Older Men with and without Parkinson's DiseaseNeurologist-associated reduction in PD-related hospitalizations and health care expendituresEvaluation and management of the non-motor features of Parkinson's disease.Response to Iraqi and Hughes.Non-motor symptoms of Parkinson's disease: the patient's perspective.Clinical characteristics of exacerbations in Parkinson disease.Advances in the treatment of visual hallucinations in neurodegenerative diseases.Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control studyVisuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges.Clinicopathological correlates of behavioral and psychological symptoms of dementia.REM sleep behavior disorder: motor manifestations and pathophysiology.Drug treatments for the neuropsychiatric complications of Parkinson's disease.The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient.Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
P2860
Q25894622-2E954A99-1897-49B4-BAB1-22AE0DA91E54Q27025380-4C4EFDE0-FDFE-41F3-9F3C-38C02A34413BQ28386548-3DAE74EB-4864-4959-A9F3-09482786B622Q29048641-B407ABB2-6599-4622-A6AD-D39D166B9BD2Q30240991-1A17EFCC-147D-4E30-A29B-55B8FA68399EQ30249553-96663F5F-EDEF-4544-884B-7A830A4FE05BQ33593735-EF3A247D-B999-4B70-B8BE-8E42404B8765Q33714196-A017B499-93E6-4F07-811E-74715C77F0F4Q33734416-5A5BE47A-71A8-4F61-B533-064BD528A67BQ33917094-6073700D-AEA7-4E9C-8BE7-C1340BC65C4AQ33957582-D472C12E-DC56-456E-AAFC-324B1077E2B6Q34080479-1F88D38C-5FA8-4D8B-812A-50A0A37EE4D1Q34370006-FA055386-9180-4BE7-B88B-8D1BB3D0F026Q34388686-B486324B-207D-434C-99DC-259D9D28785DQ34452922-65B2808C-D32D-4F8A-8587-3B64700382F8Q34574771-CA2E9227-1917-46CF-BD9D-4A5FD525CE1BQ34638941-FA85B0AC-5DA0-4EE8-B81A-080BF5446375Q34976609-D39252DE-3010-4F8E-8BFD-E3015C132317Q35016008-8DD176C0-95F4-43DB-9280-45F882E5F018Q35194993-899A8280-3DA7-4EE6-B419-B4D0105E2F27Q35892851-92D42C47-16DF-406D-BE67-65807B79DB6FQ36135045-3B80857D-331B-45FC-A342-18E21349894DQ36149712-225F3E00-22AC-4005-A233-31D169BDA1C0Q36330887-18FB85A6-4E31-4CD0-B162-F3201F52369EQ36443721-EFE3CD68-8540-4A39-9A30-C311536AC0EDQ36593130-6D05CFE7-E757-4FA3-8203-D93EED2E3C5EQ36725177-F9E3E01A-D113-4044-8269-9A4A837A55B5Q36765081-3E9D37F9-4DFB-4AB5-89DB-0BA21CCF8DF6Q37029454-C2B65B48-FACF-49AA-8E86-B231CABDFA6AQ37257345-574C7963-D7EB-4E08-9356-E7AD909E1FCEQ37505818-32D48E4B-BAD6-4B9B-9464-EBB00E141620Q37537915-13BCCC61-3C8D-4C9F-8B96-9F4966B8C161Q37697485-A22C2646-E65A-4D80-8E30-D4BE8B1E935EQ37853032-B90384A4-07AD-4FF7-851E-BD359D06B341Q37860194-716E94CA-3B4E-4C7C-970C-242FA9496E49Q37996946-8F189289-EF8F-4111-8C18-F262CD2D25E3Q38067142-2C198AD3-008E-4B28-8675-6546183894DAQ38083586-AAA7D63C-9654-428E-9939-51FC3C451F5EQ38111335-E8F98096-1675-4AA4-B8EB-621FBF220DE2Q38200546-0D5CAD85-3A61-4C6E-BDC8-899DC0FB3BCF
P2860
A 12-year population-based study of psychosis in Parkinson disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A 12-year population-based study of psychosis in Parkinson disease.
@en
A 12-year population-based study of psychosis in Parkinson disease.
@nl
type
label
A 12-year population-based study of psychosis in Parkinson disease.
@en
A 12-year population-based study of psychosis in Parkinson disease.
@nl
prefLabel
A 12-year population-based study of psychosis in Parkinson disease.
@en
A 12-year population-based study of psychosis in Parkinson disease.
@nl
P2093
P50
P1433
P1476
A 12-year population-based study of psychosis in Parkinson disease.
@en
P2093
Elin B Forsaa
Glenn T Stebbins
Jan Petter Larsen
P304
P356
10.1001/ARCHNEUROL.2010.166
P577
2010-08-01T00:00:00Z